Drug intelligence / Profile preview

Proyavit

Development stage: Unknown
Lead developer: Juvenor Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Proyavit is an oral nutraceutical product developed by Juvenor Pharmaceuticals, formulated as a combination of antioxidants, vitamins, and minerals. Its composition typically includes lycopene, vitamin A, vitamin E, vitamin C, and essential trace elements such as selenium, zinc, manganese, iodine, and copper. Proyavit is primarily used as a dietary supplement to support general health, enhance immune function, and provide antioxidant protection against oxidative stress. It is indicated for the management of nutritional deficiencies and as an adjunct in conditions where oxidative damage is a concern. The product is currently approved and marketed in India as part of Juvenor's nutritional portfolio.

Brand names: Proyavit

Targets

CA1 (Carbonic anhydrase 1)GPX1 (Glutathione peroxidase 1)RARA (Retinoic acid receptor alpha)Misfolded SOD1

Beyond the preview

Go deeper on Proyavit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proyavit.